CFDE Data Portal | Search FAM174A-DT

	Label	Description
	FAM174A-DT Gene (Entity type)	ENSG00000247877 - FAM174A divergent transcript
	GSE195568 palbociclib 2 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 10 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 7 V 5 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE82032 trametinib HCC1143 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228017 parthenolide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS

FAM174A-DT

ENSG00000247877 - FAM174A divergent transcript

GSE195568 palbociclib 2 v 10 human up

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 10 v 5 human dn

A Gene Set from LINCS

GSE120612 7 V 5 ETOPOSIDE HUMAN UP

A Gene Set from LINCS

GSE82032 trametinib HCC1143 3 v 1 human dn

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

A Gene Set from LINCS

GSE228017 parthenolide 0 v 1 human up

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 5 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.